The Pap test, a cornerstone of preventive women's health for decades, is a procedure many people avoid. The discomfort, the logistical hurdle of a clinic visit, and for some, the trauma associated with a pelvic exam, create real barriers to a life-saving screening. CELLECT Laboratories, a Waterloo-based startup founded in 2024, is building a diagnostic platform that asks a simple, radical question: what if the sample could come to the lab, not the other way around? Their answer is a proprietary nanomaterial embedded in a menstrual pad, tampon, or cup, designed to capture and stabilize cervical cells from menstrual fluid for a mail-in HPV test [Velocity Incubator] [The Forge].
The Wedge of a Familiar Sample
The company's initial focus is high-risk HPV, the primary cause of cervical cancer. The clinical bet is that the cellular material shed during menstruation contains enough analyzable DNA to match the accuracy of a traditional Pap smear or liquid-based cytology sample. The technical wedge is their patented nanomaterial, which acts to preserve the sample at room temperature, enabling it to survive postal transit to a partner laboratory [Innovation Factory]. CEO Emily De Souza and COO Ibukun Elebute are positioning the system not as a lab replacement, but as an integration layer. The sample processing and PCR analysis would be performed by existing, certified clinical labs using their standard protocols, with CELLECT providing the collection kit and the stabilized sample [The Forge] [cellectlaboratories.com]. The goal is to boost participation, particularly among under-screened populations in remote communities or those who have previously delayed care.
A Crowded Field of Non-Invasive Aspirants
CELLECT is entering a busy and ambitious segment of femtech. A growing number of companies globally are pursuing less invasive gynecological diagnostics, creating a competitive landscape where regulatory clearance and clinical validation will be the ultimate differentiators.
| Company | Location | Sample Type | Primary Focus |
|---|---|---|---|
| CELLECT Laboratories | Canada | Menstrual Fluid | HPV / Cervical Cancer |
| Daye | UK | Vaginal Swab | HPV / STIs / Vaginal Health |
| NextGen Jane | US | Menstrual Fluid | Endometriosis / Reproductive Health |
| Qvin | US | Dried Blood Spot (fingerstick) | HbA1c / Hormones (for women) |
| Emm | UK | Urine | Hormones / Fertility |
This table, drawn from the verified competitor list, shows the variety of approaches. CELLECT's specific bet on menstrual fluid for cervical cancer screening sets a clear, narrow initial target. However, the competitive pressure is not just about the sample type, but about proving clinical utility to healthcare systems and securing reimbursement pathways that are often slow to adapt.
The Long Road to the Clinic
The company's current stage is pre-commercial, supported by a patchwork of non-dilutive grants and incubator resources rather than a large priced equity round. Traction so far is measured in institutional validation and a public waitlist, not in paid pilots or FDA submissions. The path forward involves several critical, sequential milestones.
- Clinical validation. The fundamental premise that a menstrual fluid sample is diagnostically equivalent to a clinician-collected sample requires rigorous, peer-reviewed study data. Without it, the product cannot advance.
- Regulatory strategy. As a Class II medical device in the US and Canada, the collection kit will require 510(k) clearance or its Health Canada equivalent. This process is costly and time-intensive.
- Lab partnerships. The B2B2C model hinges on signing agreements with established diagnostic laboratories to process the samples, a sales motion that is new for the founders.
The ~$92,000 in disclosed grant funding from sources like the Velocity Fund and Synapse Life Science Competition is enough for prototype development and early research, but scaling to clinical trials and a regulatory filing will demand a significant venture round [CBC, Nov 2023] [Health Innovation Hub (H2i) @ U of T, Apr 2025]. The team's deep immersion in the Canadian university incubator ecosystem provides a network, but the next phase requires different capital.
What Standard Care Looks Like Today
For patients today, the standard of care for cervical cancer screening remains a clinic-based procedure. An individual visits a gynecologist or primary care provider, undergoes a speculum exam for a Pap smear or liquid-based cytology sample, and waits for results. For those with access and comfort, it is effective. For everyone else,individuals in rural areas, those without reliable transportation, people who have experienced sexual trauma, or those who simply find the exam too intimidating,it is a barrier. The consequence is a gap in screening coverage that leaves populations vulnerable to a highly preventable cancer. CELLECT Laboratories is betting that the solution can be found in a biological sample that has been routinely discarded, transforming a personal monthly experience into a powerful diagnostic tool. The ambition is humane, but the road ahead is paved with clinical and regulatory proof.
Sources
- [Velocity Incubator] CELLECT transforms cervical cancer diagnosis with nanotechnology | https://www.velocityincubator.com/news/cellect-transforms-cervical-cancer-diagnosis-with-nanotechnology
- [The Forge, McMaster University] CELLECT Laboratories Inc. | https://theforge.mcmaster.ca/startups/cellect/
- [Innovation Factory] CELLECT Laboratories Inc. | https://innovationfactory.ca/clients/cellect-laboratories-inc/
- [cellectlaboratories.com, Retrieved 2026] | https://cellectlaboratories.com
- [CBC, Nov 2023] This Waterloo startup is developing a non-invasive way to screen for cervical cancer | https://www.cbc.ca/lite/story/1.7528762?feature=random
- [Health Innovation Hub (H2i) @ U of T, Apr 2025] | https://entrepreneurs.utoronto.ca/startup/cellect-laboratories/
- [The Star, Jul 2024] To close a key gap in women’s health, this Waterloo startup is turning to an unlikely source | https://www.thestar.com/business/mars/to-close-a-key-gap-in-women-s-health-this-waterloo-startup-is-turning-to/article_16f87322-fac4-11ef-9365-bf6cff1fbdf0.html
- [Femtech Canada, Retrieved 2026] CELLECT Laboratories Inc. | https://femtech.ca/company/cellect-laboratories-inc/